Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies

Roche today announced positive topline data from two Phase III multicenter studies evaluating Xolair ® (omalizumab) for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news